Morning Overview on MSN
Pfizer settles patent fights, keeping heart drug shielded from generics to 2031
Patients taking Pfizer’s Vyndaqel and Vyndamax for a progressive, often fatal form of heart failure will not see cheaper ...
In a scant notice posted to its website on Wednesday, the European Medicines Agency (EMA) divulged that it has been hit by a cyberattack. While the agency did not reveal any details about the extent ...
Regulatory Recon: Pfizer Weighs Sale of Consumer Health Business FDA Releases Briefing Documents for Spark Gene Therapy (10 October 2017) Welcome to Regulatory Reconnaissance, your daily regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results